This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

A "Network Of Excellence" (NNE) Collaboration: Directed To Novel Therapeutic Approaches In Neurodegenerative Diseases

Stocks in this article: TEVA

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that a new and unique neuroscience research collaboration has been established to focus on novel therapeutic approaches to managing some of the most challenging diseases that society faces today.

Population growth and increased longevity are combining in a way that has seen the prevalence of brain diseases grow significantly and the burden on society has dramatically increased. Israel is a world leader in neuroscience research, ranked 5th globally in Neuroscience publications per capita. This initiative, the National Network of Excellence in Neuroscience (NNE), seeks to harness that expertise in a community drawn from 10 of the leading universities and teaching hospitals in Israel.

Working as an open-network, the NNE is directed towards the discovery and development of new treatments and approaches to counter the devastating effects of neurological, neurodegenerative and psychiatric illness. It brings the researchers together and provides a working interface with industry, where experts in drug development from Teva will interact with academic researchers in order to increase the potential to translate basic science into therapeutic options.

Research projects supported by the NNE are already providing some important clues towards progress in key treatment modalities. Some of these projects have already identified approaches to treatment which may modify the course and progression of diseases.

In Alzheimer's disease, where loss of memory and learning ability lead to most devastating effects, approaches to enhance memory are being explored. Additionally, Multiple Sclerosis and Huntington disease are two areas where new approaches that aim to stop or reverse the progression of the disease are being investigated.

"I want to beat Multiple Sclerosis and send my patients back to their lives," said Professor Anat Achiron, Director of the Multiple Sclerosis Center at Sheba Medical Center. "The NNE initiative has enabled us to progress with a new compound, which already shows promising early results towards potentially having a new treatment modality in Multiple Sclerosis, which may one day even mean we can close our wonderful MS treatment center."

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs